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Abstract The aim was to develop clinical guidelines for
multi-parametric MRI of the prostate by a group of prostate
MRI experts from the European Society of Urogenital Radi-
ology (ESUR), based on literature evidence and consensus
expert opinion. True evidence-based guidelines could not be
formulated, but a compromise, reflected by “minimal” and
“optimal” requirements has been made. The scope of these
ESUR guidelines is to promulgate high quality MRI in acqui-
sition and evaluation with the correct indications for prostate
cancer across the whole of Europe and eventually outside
Europe. The guidelines for the optimal technique and three
protocols for “detection”, “staging” and “node and bone” are
presented. The use of endorectal coil vs. pelvic phased array
coil and 1.5 vs. 3 Tis discussed. Clinical indications and a PI-
RADS classification for structured reporting are presented.
Key Points
￿ This report provides guidelines for magnetic resonance
imaging (MRI) in prostate cancer.
￿ Clinical indications, and minimal and optimal imaging
acquisition protocols are provided.
￿ A structured reporting system (PI-RADS) is described.
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Introduction
In their lifetime, 1 in 6 men will be clinically diagnosed with
prostate cancer. This accounts for annually 350,000 cases,
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DOI 10.1007/s00330-011-2377-ywhich is 25% of all new male malignancies diagnosed in
Europe [1–4]. Currently, digital rectal examination (DRE),
serum prostate specific antigen (PSA)—a non-specific blood
test—and trans-rectal ultrasound (TRUS) guided biopsy—
where the target is mostly invisible—are used as diagnostic
tools. Advances in MRI show promise for improved detection
and characterisation of prostate cancer, using a multi-
parametric approach, which combines anatomical and func-
tional data. Thus far optimal acquisition and evaluation have
notbeen agreed[5], and as is often the casein clinicalpractice,
it is not satisfactory to await conclusions from large scale
imaging and oncological trials. As a first step, the European
Society of Urogenital Radiology (ESUR) has called upon
Europe-wide expertise to produce a set of guidelines on MRI
on prostate cancer.
Methods
An ESUR working group of prostate MRI experts had infor-
mal discussions at international congresses and by e-mail.
This crystallised into a series of specialist sub-groups. The
criteria for group inclusion were radiologists with at least
3 years of experience in prostate MRI (>50/year), conducting
research comparing image results with pathological speci-
mens, co-working with urologists, and producing peer
reviewed international articles. Over a 21/2-year period five
meetings took place. Based on the recommendations of the
sub-group chairs a consensus document was established and
finalised by two consensus meetings and e-mail discussion.
Section 1: clinical use of MRI
Multi-parametric MRI
Recommended use of MRI in prostate cancer consists of
multi-parametric (mp-MRI). This includes a combination of
high-resolution T2-weighted images (T2WI), and at least two
functional MRI techniques, as these provide better character-
isation than T2WI with only one functional technique [6–9].
Within an mp-MRI examination, the relative clinical value of
its component techniques differs. In addition to T2WI MRI,
which mainly assesses anatomy, diffusion weighted imaging
(DWI) [10–15] and MR spectroscopic imaging (MRSI) [16,
17] add specificity to lesion characterisation, while dynamic
contrast enhanced MRI (DCE-MRI) has a high sensitivity in
cancer detection [9, 18, 19].
Clinical use of MRI
If PSA is elevated (>3–4 ng/mL) or DRE indicates sus-
pected tumour, TRUS-guided biopsy will be performed to
detect potential cancer, and assess its extent, volume and
aggression. But, PSA has low specificity (36%), thus in-
creased PSA is not equivalent with tumour. Also, normal
PSA does not exclude tumour. Finally, TRUS biopsy under-
estimates the extent and grade of prostate cancer.
Based on PSA findings, DRE results and histopathological
findings at TRUS biopsy, treatment is determined. Localised
prostate cancer can be stratified into three groups based on the
likelihood of tumour spread and recurrence:
& Low-risk: PSA <10 ng/mL, and biopsy Gleason score
≤6, and clinical stage T1–T2a
& Intermediate-risk: PSA 10–20 ng/mL, or biopsy Gleason
score 7, or clinical stage T2b or T2c
& High-risk: PSA >20 ng/mL, or Gleason score 8–10, or
clinical stage >T2c.
Treatment options: role of MRI
Decisions about imaging patients with newly diagnosed pros-
tate cancer are determined by “intention to treat” (see Table 1).
Low-risk patients Treatment intention is radical surgery, ra-
diotherapy or active surveillance (AS). Mp-MRI can be help-
ful in managing low risk patients and guide them towards AS,
by confirming the absence of significant intra-prostatic dis-
ease. Additionally, mp-MRI can be used to help nerve and
continence sparing surgery, and to focus radiotherapy.
Intermediate-risk patients Being staged for curative intent.
In this group the chance of extra-prostatic spread rises
significantly. Thus it is advisable to perform mp-MRI in
this group for detecting minimal extra-capsular disease by
means of a “staging protocol” (Table 2B).
Table 1 Treatment options: role of MRI
Life expectancy Active surveillance Radical surgery Radiotherapy Hormones
Localised 10–15 year estimated life expectancy
(Generally these patients will be
younger than 75)
Yes Yes—consider
nerve sparing
External or brachytherapy No
Localised Less than 10–15 years Yes Rarely External or brachytherapy No
Locally advanced Any No No In combination with hormones Yes
Metastatic Any No No Palliative Yes
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phy or MRI to detect skeletal or nodal metastases is
recommended. Here the “node and bone protocol” is
advised (see Table 2C). If information is required about
the local stage, the “staging protocol” may additionally be
performed.
Lymph node staging of prostate cancer using convention-
al MRI is unreliable, as 70% of metastatic lymph nodes in
prostate cancer are often small (<8 mm). If however, the a
priori risk of having nodal metastases is >40%, MRI or CT
should be performed [20]. Urologists use a lower a priori
threshold of10–17% toperform pelviclymph nodedissection
[20].
MRI to determine tumour aggression
Mp-MRI techniques give increased conspicuity of tumour
detection within the prostate and highlight areas of more
aggressive disease within a short examination time (“detec-
tion protocol”, Table 2A). The prediction of the Gleason
score is better assessed by DWI and
1H-MRSI compared
with T2WI and DCE-MRI [21].
In low-risk patients considered for AS, monitoring involves
[22–27]:
& PSA testing—every 3 months for 2 years, then every
6 months
& Regular DRE
& Repeat prostate TRUS-guided biopsies every 2–3 years.
Mp-MRI before AS is advocated, as it allows detection of
adverse prognostic features such as tumour volume, and
higher grade tumours, particularly in the anterior and apical
lesions. DCE-MRI and DWI plus T2WI are highly accurate
in detecting tumours >0.5 cc volume [18, 28]. Furthermore,
MRSI plus T2WI have been reported to be very helpful in
both excluding and detecting high-grade cancers >0.5 cc
(sensitivity 93%, NPV 98%) [29, 30]. The results of mp-
MRI can be used to direct further biopsy for more accurate
grading of the tumour.
Table 2 Acquisition protocols: minimum requirements
A. Detection protocol
Fast <30-min protocol without an endorectal coil (ERC). Images should cover entire prostate, and include T2WI, DWI and DCE-MRI. Imaging
can adequately be performed at 1.5 T using a good 8- to 16-channel pelvic phased array (PPA). Anti-peristaltic drugs (Buscopan®, Glucagon®)
should be given.
￿ T2WI axial+sagittal: 4 mm at 1.5 T, 3 mm at 3 T; in plane resolution: 0.5×0.5 mm to 0.7×0.7 mm at both 1.5 T and 3 T.
￿ DWI axial: 5 mm at 1.5 T, 4 mm at 3 T; in-plane resolution: 1.5×1.5 mm to 2.0×2.0 mm at 1.5 T and 1.0×1.0 mm to 1.5×1.5 mm at 3 T.
ADC map should be calculated. At least 3 b-values should be acquired in three orthogonal directions and adapted to quality of SNR: 0, 100 and
800–1000 s/mm
2. For calculation of ADC, the highest b-value that should be used is 1000 s/mm
2.
￿ DCE-MRI axial: 4 mm at 1.5 T and 3 T; in plane resolution: 1.0×1.0 mm at 1.5 T and 0.7×0.7 mm at 3 T. Quantitative or semi-quantitative
DCE-MRI analysis does not have to be performed. Maximum temporal resolution should be 15 s following single dose of contrast agent with
an injection rate of 3 mL/s. For DCE-MRI, imaging acquisition should be continued for 5 min to detect washout. Unenhanced T1WI images
from this sequence can be used to detect post-biopsy haematomas.
￿ MRSI: optionally, MRSI can be added to the detection protocol, but this requires an extra 10–15 min of examination time. For this ERC is
mandatory at 1.5 T and optional at 3 T; volume of interest (VOI) aligned to axial T2WI; coverage of the whole prostate in the VOI; field of
view at least 1.5 voxels larger than the VOI in all directions to avoid wrap-around or back folding; matrix of at least 8 x 8 x 8 phase-encoding
steps with nominal voxel size <0.5 cc; spectral selective suppression of water and lipid signals; positioning of at least six fat saturation bands
close to the prostatic margin (may be positioned inside the VOI) to conform to the prostatic shape as closely as possible; automatic or manual
shimming up to a line width at half height of the water resonance peak between 15 and 20 Hz at 1.5 T and between 20 and 25 Hz at 3 T.
B. Staging protocol
45-min protocol for evaluating minimal extra-capsular extension. Preferably, this examination should be done with an ERC. Images should include
entire prostate, with anti-peristaltic drugs.
￿ T2WI axial, coronal and sagittal planes, 3 mm at 1.5 Tand 3 T; in plane resolution: 0.3×0.3 mm to 0.7×0.7 mm at 1.5 Tand 0.3×0.3 mm to
0.5×0.5 mm at 3 T.
￿ DWI and DCE as detection protocol.
￿ MRSI optional.
C. Nodes and bone protocol
30-min protocol, to assess nodal size and bone marrow metastases. Should be performed separately from A and B, as most patients do not require
bone or node staging.
￿ T1WI coronal of lower lumbar spine plus pelvis (SE or f/T SE) 3.0-mm slices
￿ 3D f/T SE T2WI coronal of lower lumbar spine plus pelvis; 1.0-mm isometric voxels
￿ DWI coronal of lower lumbar spine plus pelvis (b-values 0 and 600); slice thickness 3–4 mm, in plane resolution: 2.5–3.0 mm voxels
￿ T1WI sagittal cervical and thoracic spine (SE or f/T SE)
￿ STIR or DWI sagittal cervical and thoracic spine.
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with negative previous TRUS biopsy
When TRUS biopsy is negative, and an interval rise in PSA
justifies further investigation, mp-MRI using the “detection
protocol” (Table 2A) must be applied before further TRUS-
guided biopsy. MR-guided biopsy based on mp-MRI has
shown superior results [21, 31–34]. Figure 1 summarises the
role of MRI in undiagnosed and primary diagnosed prostate
cancer.
Investigating men post-therapy with PSA rise
Mp-MRI can be considered to be a tool to evaluate the
prostatic fossa in patients with low PSA recurrence (values
ranged between 0.2–2 ng/mL) where according to the EAU,
other techniques (PET, TRUS biopsy) are not recommended
[35]. When curative aggressive treatment (e.g. salvage ra-
diotherapy) is considered, in addition to T2WI, DCE-MRI
and DWI should always be performed using the “detection
protocol” [36–39]. Nodes and bone can be evaluated with
the “node and bone” protocol.
Section 2: MRI sequences for prostate gland evaluation
T2-weighted MR imaging
T2-weighted imaging (T2WI) provides the best depiction of
the prostate’s zonal anatomy and capsule. T2WI is used for
prostate cancer detection, localisation and staging. T2WI
alone is not recommended because additional functional
techniques improve both sensitivity and specificity. T2WI
are obtained in 2–3 planes. The axial T2WI sequence must
cover the entire prostate and seminal vesicles, and are
orthogonal to the rectum. The phase encoding direction
is left-to-right so that motion artefact does not overlap
the prostate. Bowel motion artefacts should be reduced
by administering an anti-peristaltic agent. The patient
should be instructed about the importance of not mov-
ing during image acquisition. An endorectal coil (ERC)
is not an absolute requirement at either 1.5 T or 3 T,
but a pelvic phased array (PPA) coil with a minimum of
16 channels is required.
Prostate cancer typically manifests as a round or ill-
defined, low-signal-intensity focus in the peripheral zone
(PZ; Fig. 2a). However, various conditions such as prostate
intra-epithelial neoplasia, prostatitis, haemorrhage, atrophy,
scars and post-treatment changes can mimic cancer on
T2WI. Tumours located in the transition zone (TZ) are more
challenging to detect, as the signal intensity characteristics of
the TZ and cancer usually overlap [40]. TZ tumour is often
shown as a homogeneous signal mass with indistinct margins
(“erased charcoal sign”,F i g .3a, f). A lenticular (Fig. 3a)o r
“water-drop” shape is typical. These tumours often invade the
pseudo-capsule with extension into the transition zone, or
anterior fibro-muscular zone [40]. High-grade cancers tend
to have a lower SI than low-grade cancers [41].
The interpretation of T2WI includes evaluation of the
capsule, seminal vesicles and posterior bladder wall for
extra-prostatic tumour invasion. Criteria for extra-capsular
extension are abutment; irregularity and neurovascular bun-
dle thickening; bulge, loss of capsule and capsular enhance-
ment; measurable extra-capsular disease; obliteration of the
recto-prostatic angle. For seminal vesicle infiltration the
criteria are: expansion; low T2 signal intensity; filling in
of the prostate–seminal vesicle angle; enhancement and
impeded diffusion (see Table 4).
First presentation 
TRUS-biopsy 
(10-14 cores)
Biopsy positive 
#  of cores 
% of each core positive 
Biopsy negative 
Clinical follow up 
Re-measure PSA 
Curative intent 
Patient factors: life 
expectancy, co-
morbidities, preference 
Active surveillance
Staging MRI 
with bone and node MRI
in high risk (PSA>15 or 
Gleason>7, or DRE T3) 
Biopsy negative and 
clinical suspicion PCa 
Staging MRI to confirm 
grade and extent T2WI, 
DWI, DCE, (MRSI)
Detection MRI and then 
biopsy (TRUS guided by 
MRI or MR-guided biopsy 
in some specialist units) 
Fig. 1 Algorithm in imaging
men referred with elevated
serum prostate specific antigen
(PSA), abnormal digital rectal
examination (DRE), or family
history of prostate cancer
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T2WI alone is sensitive but not specific for prostate cancer
and should be improved using two functional techniques.
Lesion detection is particularly problematic in the TZ
because benign prostatic hyperplasia (BPH) looks like can-
cer [42]. However, presence of an “erased charcoal sign” in
a lenticular lesion is highly suggestive of cancer.
Biopsy-related haemorrhage can cause artefacts that mimic
cancer and limit lesion localisation and staging. To prevent
this, the time interval between the biopsy procedure and MRI
should be at least 4–6w e e k s[ 41] and preliminary T1WI can
be done to exclude biopsy-related haemorrhage. If significant
haemorrhageisseen,thepatientcanberescheduled3–4weeks
later to allow resolution of the haemorrhage.
Dynamic contrast enhanced MRI
Dynamiccontrastenhanced(DCE)MRIfollowing theadmin-
istration of gadolinium-based contrast medium is the most
common imaging method for evaluating tumour vascularity
[43]. As normal prostate is also highly vascular, a comparison
of pre- and post-gadolinium images is usually insufficient to
discern prostate cancer [44, 45]. A fast and direct method of
characterising prostatic vascular pharmacokinetic features is
high temporal resolution DCE-MRI (<10 s). DCE-MRI con-
sists of a series of axial T1WI gradient echo sequences
coveringtheentireprostateduringand after IVbolus injection
(2–4 mL/s) of gadolinium-based contrast medium [46, 47].
T1WI DCE-MRI imaging data can be assessed in three ways:
qualitatively, semi-quantitatively or quantitatively.
DCE-MRI for prostate cancer detection, localisation, staging
and recurrence detection Hara et al have shown that DCE-
MRI is able to detect clinically important prostate cancer in
93% of cases [48]. In patients with previous negative
TRUS-guided biopsy sessions and rising PSA level, DCE-
MRI plays an important role in lesion detection (Fig. 3d,e )
[49].
Several studies have found that DCE-MRI is superior to
T2WI for prostate cancer localisation.
Althoughthe literatureissparse, available datasuggest that
DCE may improve staging. Thus, DCE-MRI is essential for
the detection ofpost-prostatectomy[36, 37] and -radiotherapy
recurrences [38, 39].
Caveats and conclusions
Dynamic contrast enhanced MRI is a valuable tool for MRI
of prostate cancer, improving tumour localisation and local
staging. However, it should always be combined with T2WI
and DWI, as discrimination among prostatitis, BPH and
prostate cancer in the TZ is more challenging with DCE-
MRI alone.
Diffusion weighted MRI
Diffusion weighted imaging (DWI) is a powerful clinical
tool, as it allows apparent diffusion coefficient (ADC) maps
to be calculated, enabling qualitative and quantitative as-
sessment of prostate cancer aggressiveness. Cancer shows a
lower ADC value than normal prostate tissue. Furthermore
ADC values correlate with Gleason scores [10–15].
Diffusion weighted imaging should be acquired in the axial
plane withanechoplanarimaging sequence employingparallel
imaging. Motion probing gradients should be applied in three
orthogonal directions and adapted to the quality of the SNR.
The minimal requirements are b-values of 0, 100, and 800–
1000 s/mm
2. The choice of these values enables calculation
of diffusion sensitive ADC values (by excluding the b0
0 data from the ADC calculation). For optimal DWI, the b-
valuesare:0,100,500,and800–1000s/mm
2.TEsh ou ldbeas
short as achievable (typically <90 ms).
Fig. 2 A 65-year-oldman withstageT3aGleason 4+3 prostate cancer at
theleft peripheral zone(PZ).a On the axialT2WI atmid-prostatelevel in
the left PZ there is a low signal lesion (outlined) with obliteration of the
recto-prostatic angle and extra-capsular extension (arrow). b Magnetic
resonance spectroscopic imaging (MRSI) of the normal right side shows
low choline+creatine, whereas on (c) MRSI of the tumour shows high
choline+creatine. The choline peak of tumour is as equally as high as the
citrate peak. This results in a PI-RADS score for MRSI of 3
750 Eur Radiol (2012) 22:746–757Apparent diffusion coefficient maps can be generated
from the index DWI data on the MR console itself, and
have to be analysed qualitatively and quantitatively.
Prostate cancer demonstrates high signal intensity on
DWI at high b-values and low signal intensity/value on
ADC maps [50–52]. For qualitative assessment high b-
value (800–1000) DW images and ADC maps should be
used. These should be evaluated in combination with T2WI
for the anatomical detail. However, some normal prostatic
tissue, especially in the TZ, may reveal high signal intensity
on DWI and low ADC, thus mimicking tumour. This may
be overcome by using very high b-values (>1000 s/mm
2).
For quantitative assessment ADC values are used. How-
ever, there is variability when using different field strengths,
different b-values, and different models to fit the data. Also,
there is a considerable inter-patient variability. Thus abso-
lute values should be used with care. Until now DWI has not
given additional information for staging.
Caveats and conclusions
Diffusion weighted imaging is an essential component of
mp-MRI (Fig. 3a–c). It provides information about tumour
aggressiveness, and improves specificity in prostate cancer
Fig. 3 A 75-year-old man. After five negative trans-rectal ultrasound
(TRUS) biopsies PSA rose to 32 ng/mL, PCa3062. Multi-parametric
(Mp)-MRI was performed. a On axial T2WI there is a lenticular area
with homogeneous low signal intensity (SI) and unsharp borders:
“erased charcoal sign” (outlined), in the mid-prostate level in ventral
transition zone (TZ) which is located anterior to the “organised chaos”
of benign prostatic hyperplasia (BPH). This pathological area origi-
nates from anterior fibromuscular stroma, and thus has a PI-RADS
T2WI score of 5. b On the apparent diffusion coefficient (ADC) map
this region has a minimum ADC value of 650 (dark area); c On the b0
1400 image this area is white. This results in a PI-RADS score for
diffusion weighted imaging (DWI) of 5. d This region shows a curve
t y p e3( w a s h - o u t ) ,a n do n( e)T 2 W Iw i t hk trans overlay, there is
asymmetric, rather focal enhancement. This gives a PI-RADS score
for dynamic contrast enhanced (DCE) MRI of 3+205. f shows the
anterior location of the tumour on sagittal T2WI. As MRSI was not
performed the sum PI-RADS score is 15/15, which argues in favour of
an aggressive (significant) tumour. Thus the overall PI-RADS score for
probability of being a significant cancer is 5. MR-guided biopsy
revealed a Gleason 4+509 tumour. As the images clearly indicate a
tumour, one may argue that one of the parameters may be obviated.
However, mp-MRI is not only meant to “detect” a tumour, but also to
predict its aggression. If all parameters point into the same direction,
the chance of a clinically “significant” tumour (that is Gleason 4+3 or
higher) is extremely high. If there is discordance it may be prostatitis or
an insignificant (Gleason 3+3) cancer
Eur Radiol (2012) 22:746–757 751detection compared with T2WI alone. DWI correlates well
with tumour volume of the index prostatic lesions. It should,
therefore, be part of routine assessments of patients with
prostate cancer.
Diffusion weighted imaging is, however, affected by mag-
netic susceptibility effects resulting in spatial distortion and
signal loss. Large b-values are required to suppress normal
prostate tissue background signal and ADC maps should be
used to minimise T2 shine-through [50].
MR spectroscopic imaging
Magnetic resonance spectroscopic imaging (MRSI) is able
to show the lower levels of citrate and higher levels of
choline of prostate cancer compared with benign tissue
[53]. MRSI is performed with a 3D chemical shift imaging
protocol (details can be found in Appendix 3). The use of an
ERC is imperative at 1.5 T, but optional at 3 T. The volume
of interest (VOI) is aligned to axial T2WIs to maximise
coverage of the whole prostate, while minimising contami-
nation by surrounding tissue. It is partitioned into a matrix
of at least 8×8×8 phase-encoding steps. Applying spectral
selective water and lipid suppression close to the prostatic
margins reduces unwanted water and lipid signals in the
VOI.
After post-processing, using commercially available soft-
ware packages, spectral information is overlaid on T2WIs.
The relevant metabolites are citrate (marker of benign tis-
sue), creatine (insignificant for diagnosis, but difficult to
resolve from choline), and choline (marker of malignant
tissue). In quantitative analysis, the peak integrals of all
metabolites are estimated by means of the choline-plus-
creatine-to-citrate (CC/C) ratio. Cancer in PZ and TZ should
have in at least two adjacent voxels a CC/C ratio exceeding
respectively 2 and 3 standard deviations above the mean
ratio [53–57]. In qualitative analysis, the peak heights of
citrate and choline are visually compared (Fig. 2b,c )[ 58].
Magnetic resonance spectroscopic imaging can be used to
predict the presence or absence of cancer [21, 29, 30]. It
also provides information about lesion aggressiveness, but
does not give staging information owing to its poor
spatial resolution. Thus, MRSI is a valid toolfordetecting
cancer recurrence [59–65] and monitoring therapy response
[66].
Caveats and conclusions
Magnetic resonance spectroscopic imaging provides valu-
able information about lesion aggression, but requires ex-
pertise, use of an endorectal coil at 1.5 T, and adds time to
the examination. Whether MRSI is included in the mp-MRI
examination depends on personal local experience and
availability.
Section 3. MR equipment
MR coils
The ERC+PPA coil combination provides excellent SNR
and remains state-of-the-art for staging prostate cancer.
However, it has recognised drawbacks in terms of cost and
patient acceptability.
Many articles have shown good results in tumour detec-
tion/localisation without the ERC when the mp-MRI ap-
proach is used. Further work is, however, necessary to:
a. Compare tumour detection/localisation, and staging ac-
curacy of PPA vs. ERC+PPA coil MRI.
b. Assess the clinical relevance of minimal extra-prostatic
disease detected by ERC usage.
Imaging at 3 T
Prostateimagingat3TbenefitsfromhigherSNR,andenables
high quality imaging within a short time without the use of an
ERC. Data on 3 T for prostate cancer MRI are still conflicting
[67]. Thus further research on this topic is needed
Limitations of 3 T MRI are shorter T2 and longer T1
relaxation times [68], problems with susceptibility arte-
facts [69, 70], dielectric effect, specific absorption rate
[71], and the homogeneity of the magnetic field. How-
ever, hardware, multi-channel coil, and parallel imaging
technique improvements are currently solving most of
these problems.
Section 4. Integration, reporting and communication
of multi-parametric prostate MRI data
Mp-MRI data need to be presented to clinical colleagues in a
simple but meaningful way, preferably using a structured
reporting scheme, which consists of the following items:
& PI-RADS score which relays the probability of cancer
risk and its aggression, plotted on a scheme
& Location and, probability of extra-prostatic disease
& Pertinent incidental findings.
Scoring system for mp-MRI (PI-RADS)
A scoring system similar to that employed successfully by
breast radiologists (BI-RADS for X-ray mammography,
breast ultrasound and MRI) should be used and prospective-
ly validated for prostate mp-MRI. Scoring should include:
1. As a minimum requirement division of the prostate 16
regions, as an optimal requirement into 27 regions.
752 Eur Radiol (2012) 22:746–757Table 3 PI-RADS scoring system
Score Criteria
A1. T2WI for the peripheral zone (PZ)
1 Uniform high signal intensity (SI)
2 Linear, wedge shaped, or geographic areas of lower SI, usually not well demarcated
3 Intermediate appearances not in categories 1/2 or 4/5
4 Discrete, homogeneous low signal focus/mass confined to the prostate
5 Discrete, homogeneous low signal intensity focus with extra-capsular extension/invasive behaviour or mass effect on the capsule (bulging),
or broad (>1.5 cm) contact with the surface
A2. T2WI for the transition zone (TZ)
1 Heterogeneous TZ adenoma with well-defined margins: “organised chaos”
2 Areas of more homogeneous low SI, however well marginated, originating from the TZ/BPH
3 Intermediate appearances not in categories 1/2 or 4/5
4 Areas of more homogeneous low SI, ill defined: “erased charcoal sign”
5 Same as 4, but involving the anterior fibromuscular stroma or the anterior horn of the PZ, usually lenticular or water-drop shaped.
B. Diffusion weighted imaging (DWI)
1 No reduction in ADC compared with normal glandular tissue. No increase in SI on any high b-value image (≥b800)
2 Diffuse, hyper SI on ≥b800 image with low ADC; no focal features, however, linear, triangular or geographical features are allowed
3 Intermediate appearances not in categories 1/2 or 4/5
4 Focal area(s) of reduced ADC but iso-intense SI on high b-value images (≥b800)
5 Focal area/mass of hyper SI on the high b-value images (≥b800) with reduced ADC
C. Dynamic contrast enhanced (DCE)-MRI
1 Type 1 enhancement curve
2 Type 2 enhancement curve
3 Type 3 enhancement curve
+1 For focal enhancing lesion with curve type 2–3
+1 For asymmetric lesion or lesion at an unusual place with curve type 2–3
D1. Quantitative MRS for 1.5 T. Diagram references [50, 70]
Eur Radiol (2012) 22:746–757 7532. Individual lesions being given a (PI-RADS) score.
3. Maximum dimension of the largest abnormal lesion.
Reviews of the literature show that Likert-like five-grade
scoring systems are often used to evaluate mp-MRI of the
prostate [28, 72–76]. In keeping with this, a recent consen-
sus meeting of prostate cancer experts used the UCLA-
RAND appropriateness method and recommended that a
five-point scale be used for the PI-RADS scoring:
Score 1 0 Clinically significant disease is highly un-
likely to be present
Score 2 0 Clinically significant cancer is unlikely to be
present
Score 3 0 Clinically significant cancer is equivocal
Score 4 0 Clinically significant cancer is likely to be
present
Score 5 0 Clinically significant cancer is highly likely
to be present.
The criteria for assigning scores to lesions identified by
each technique are not yet generally accepted. The most
developed is the quantitative evaluation of 1H-MRSI [57,
76]. Based on consensus opinion and literature evidence the
ESUR experts propose to use the PI-RADS classification,
which is presented in Table 3. In this scoring system every
parameter: T2WI (PZ and TZ different description), DWI,
DCE-MRI and MRSI is scored on a five-point scale. Addi-
tionally, each lesion is given an overall score, to predict its
chance of being a clinically significant cancer.
Table 4 Scoring of extra-
prostatic disease Criteria Findings Score
Extra-capsular extension Abutment 1
Irregularity 3
Neurovascular bundle thickening 4
Bulge, loss of capsule 4
Measurable extra-capsular disease 5
Seminal vesicles Expansion 1
Low T2 signal 2
Filling in of angle 3
Enhancement and impeded diffusion 4
Distal sphincter Adjacent tumour 3
Effacement of low signal sphincter muscle 3
Abnormal enhancement extending into sphincter 4
Bladder neck Adjacent tumour 2
Loss of low T2 signal in bladder muscle 3
Abnormal enhancement extending into bladder neck 4
Table 3 (continued)
Score Criteria
D2. Qualitative magnetic resonance spectroscopic imaging (MRSI)
1 Citrate peak height exceeds choline peak height >2 times
2 Citrate peak height exceeds choline peak height times >1, <2 times
3 Choline peak height equals citrate peak height
4 Choline peak height exceeds citrate peak height >1, <2 times
5 Choline peak height exceeds citrate peak height >2 times
In qualitative analysis, the relative peak heights of citrate and choline are visually compared (pattern analysis), rather than quantified. The criteria
apply for 1.5: for at least three adjacent voxels
Score 1 0 Clinically significant disease is highly unlikely to be present
Score 2 0 Clinically significant cancer is unlikely to be present
Score 3 0 Clinically significant cancer is equivocal
Score 4 0 Clinically significant cancer is likely to be present
Score 5 0 Clinically significant cancer is highly likely to be present
754 Eur Radiol (2012) 22:746–757In addition to Table 3, for quantitative analysis of 1.5 T
MRSI, the following score can be used:
At least two adjacent voxels with CC/C ratios, which
have:
– >4 standard deviations from the mean normal value: 5
points
– >3–4 standard deviations from the mean normal value:
4 points
– >2–3 standard deviations from the mean normal value:
3 points
– >1–2 standard deviations from the mean normal value:
2 points
– ≤1 standard deviation from the mean normal value: 1 point
In addition to the PI-RADS score for the probability of a
lesion to be significant, extra-prostatic involvement should also
be scored on a five-point scale (Table 4). This should include:
extra-capsular extension, seminal vesicle infiltration, distal
sphincter, rectal wall, neurovascular bundles and bladder neck.
Here, also, all aspects should have a scoring range of 1 to 5.
Conclusion and considerations
These recommendations argue cogently that mp-MRI should
be an integral part of prostate cancer diagnosis and treatment.
Although disputed by some urologists [68], the minimal
requirements for the acquisition of MR images can be met
with the generally available 1.5- and 3-T MR systems.
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